Biotechnology Johnson & Johnson’s Carvykti Stands Ahead Of Bristol Myers’ Rival Blood Cancer Therapy With FDA Approval For Wider Population – Legend Biotech (NASDAQ:LEGN), Johnson & Johnson (NYSE:JNJ) Read more
Biotechnology Arcellx’s Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson’s Multiple Myeloma Cell Therapies: Morgan Stanley – Arcellx (NASDAQ:ACLX) Read more
Biotechnology FDA Approves Johnson & Johnson’s Reduced Tecvayli Dosing In Pretreated Multiple Myeloma Patients – Johnson & Johnson (NYSE:JNJ) Read more
Biotechnology New Hope For Patients With Chronic Autoimmune Conditions: Johnson & Johnson’s Investigational Drug Meets Primary Goal In Two Studies – Johnson & Johnson (NYSE:JNJ) Read more